Enterprise Value

1.065B

Cash

776.9M

Avg Qtr Burn

-74.02M

Short % of Float

13.98%

Insider Ownership

1.62%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Data readout

PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details
Beta thalessemia

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Update

AG-946 Details
Myelodysplastic syndrome

Phase 2b

Initiation